Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Treasury Shares (2022 - 2025)

Axsome Therapeutics' Treasury Shares history spans 4 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 11.67% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, up 11.67%, while the annual FY2025 figure was $1.0 million, 11.67% up from the prior year.
  • Treasury Shares for Q4 2025 was $1.0 million at Axsome Therapeutics, up from $64281.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.0 million in Q2 2025 and bottomed at $64281.0 in Q1 2025.
  • The 4-year median for Treasury Shares is $792710.0 (2023), against an average of $732884.1.
  • The largest annual shift saw Treasury Shares rose 17.95% in 2023 before it tumbled 93.03% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $686375.0 in 2022, then rose by 17.16% to $804150.0 in 2023, then grew by 12.78% to $906944.0 in 2024, then increased by 11.67% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Treasury Shares are $1.0 million (Q4 2025), $64281.0 (Q3 2025), and $1.0 million (Q2 2025).